CHRISTOPHER LEE CORLESS, MD
Medical Practice at Sam Jackson Park Rd, Portland, OR
License number
Oregon MD19127
Category
Medical Practice
Type
Anatomic Pathology
Address
Address
3181 SW Sam Jackson Park Rd, Portland, OR 97239
Phone
(503) 494-8276
Personal information
See more information about CHRISTOPHER LEE CORLESS at radaris.comName
Address
Phone
4904 SW Dosch Park Ln, Portland, OR 97239
4904 Dosch Park Ln, Portland, OR 97239
Professional information
Co-Director, Molecular Diagnostics At Oregon Health &Amp; Science University Professor Of Pathology At Oregon Health &Amp; Science University Medical Director, Surgical Pathology At Oregon Health &Amp; Science University See Less...
Location:
Portland, Oregon Area
Industry:
Biotechnology
Experience:
Oregon Health & Science University (Hospital & Health Care industry): Co-Director, Molecular Diagnostics, (2007-Present) I serve as co-director of the Pathology Translational Research Laboratory. My interest is in molecular diagnostics for solid tumors and hematologic ma...
Christopher Lee Corless, Portland OR
Specialties:
Pathologist
Address:
3181 Sw Sam Jackson Park Rd, Portland, OR 97239
Education:
Doctor of Medicine
Board certifications:
American Board of Pathology Certification in Anatomic Pathology (Pathology)
Christopher Lee Corless, Portland OR
Specialties:
Pathology, Anatomic Pathology
Work:
Oregon Health & Science University
3181 SW Sam Jackson Park Rd, Portland, OR 97239
3181 SW Sam Jackson Park Rd, Portland, OR 97239
Education:
Washington University at St. Louis (1988)
Dr. Christopher L Corless, Portland OR - MD (Doctor of Medicine)
Specialties:
Anatomic Pathology
Address:
OREGON HEALTH AND SCIENCE UNIVERSITY
3181 SW Sam Jackson Park Rd, Portland 97239
(503) 494-8311 (Phone), (503) 494-3092 (Fax)
Oregon Health Scn Univ Hosp PTH
3181 SW Sam Jackson Park Rd SUITE L47, Portland 97239
(503) 494-8276 (Phone)
OREGON HEALTH AND SCIENCE UNIVERSITY
3181 SW Sam Jackson Park Rd, Portland 97239
(503) 494-8311 (Phone), (503) 494-4997 (Fax)
3181 SW Sam Jackson Park Rd, Portland 97239
(503) 494-8311 (Phone), (503) 494-3092 (Fax)
Oregon Health Scn Univ Hosp PTH
3181 SW Sam Jackson Park Rd SUITE L47, Portland 97239
(503) 494-8276 (Phone)
OREGON HEALTH AND SCIENCE UNIVERSITY
3181 SW Sam Jackson Park Rd, Portland 97239
(503) 494-8311 (Phone), (503) 494-4997 (Fax)
Certifications:
Anatomic Pathology, 1993
Awards:
Healthgrades Honor Roll
Languages:
English
Education:
Medical School
Washington Center / School of Medicine
Graduated: 1988
Washington Center / School of Medicine
Graduated: 1988
Activating Mutations Of Platelet Derived Growth Factor Receptor Alpha (Pdgfra) As Diagnostic Markers And Therapeutics Targets
US Patent:
2006008, Apr 20, 2006
Filed:
Jun 13, 2003
Appl. No.:
10/517905
Inventors:
Michael Heinrich - Lake Oswego OR, US
Christopher Corless - Portland OR, US
Christopher Corless - Portland OR, US
Assignee:
Brigham And Women's Hospital - Boston MA
Oregon Health & Science University - Portland OR
Dana-Farber Cancer Institute - Boston MA
Oregon Health & Science University - Portland OR
Dana-Farber Cancer Institute - Boston MA
International Classification:
C07K 14/71, C07H 21/04, C12P 21/06
US Classification:
435069100, 435320100, 435325000, 530350000, 536023500
Abstract:
This disclosure provides tyrosine kinase protein and nucleic acid variants, particularly PDGFRA variants, which are activating forms of these molecules and are linked to neoplasms and/or the development or progression of cancer. The disclosure further provides methods of diagnosis and prognosis, and development of new therapeutic agents using these molecules and fragments thereof, and kits for employing these methods and compositions.
Use Of 4-(4-Methylpiperazin-1-Ylmethyl)-N-[4-Methyl-3-(4-Pyridin-3-Yl)Pyrimidin-2-Ylamino)Phenyl]-Benzamide For Treating Seminomas
US Patent:
2005015, Jul 14, 2005
Filed:
Feb 17, 2003
Appl. No.:
10/504896
Inventors:
Michael Heinrich - Lake Oswego OR, US
Christopher Corless - Portland OR, US
Kathleen Kemmer - Baltimore MD, US
Christopher Corless - Portland OR, US
Kathleen Kemmer - Baltimore MD, US
International Classification:
A61K031/506
US Classification:
514252180
Abstract:
4-(4-methylpiperazin-1-ylmethyl)-N-[4-methyl-3-(4-pyridin-3-yl)pyrimidin-2-ylamino)phenyl]-benzamide of the formula I
or a pharmaceutically acceptable salt thereof can be used in the treatment of seminomas.
Platelet Derived Growth Factor Receptor Alpha (Pdgfra) Polypeptides Comprising Activating Mutation(S)
US Patent:
8202969, Jun 19, 2012
Filed:
Dec 3, 2010
Appl. No.:
12/959588
Inventors:
Michael C. Heinrich - Lake Oswego OR, US
Christopher C. Corless - Portland OR, US
Jonathan A. Fletcher - Brookline MA, US
George D. Demetri - Brookline MA, US
Christopher C. Corless - Portland OR, US
Jonathan A. Fletcher - Brookline MA, US
George D. Demetri - Brookline MA, US
Assignee:
Oregon Health & Science University - Portland OR
U.S. Department of Veteran Affairs - Washington DC
Dana-Farber Cancer Institute - Boston MA
Brigham and Women's Hospital - Boston MA
U.S. Department of Veteran Affairs - Washington DC
Dana-Farber Cancer Institute - Boston MA
Brigham and Women's Hospital - Boston MA
International Classification:
C07K 14/71, C07K 16/30, C07K 7/00, A61K 39/395, G01N 33/574
US Classification:
530350, 435 723, 4241381, 4241391, 4241431, 530300, 5303877, 5303879, 53038822, 514 75
Abstract:
This disclosure provides tyrosine kinase protein and nucleic acid variants, particularly PDGFRA variants, which are activating forms of these molecules and are linked to neoplasms and/or the development or progression of cancer. The disclosure further provides methods of diagnosis and prognosis, and development of new therapeutic agents using these molecules and fragments thereof, and kits for employing these methods and compositions.
Nucleic Acids Encoding Platelet Derived Growth Factor Receptor Alpha (Pdgfra) Activating Mutations
US Patent:
7875710, Jan 25, 2011
Filed:
May 14, 2009
Appl. No.:
12/466218
Inventors:
Michael C. Heinrich - Lake Oswego OR, US
Christopher C. Corless - Portland OR, US
Jonathan A. Fletcher - Brookline MA, US
George D. Demetri - Brookline MA, US
Christopher C. Corless - Portland OR, US
Jonathan A. Fletcher - Brookline MA, US
George D. Demetri - Brookline MA, US
Assignee:
Oregon Health & Science University - Portland OR
The United States of America as represented by the Department of Veterans Affairs - Washington DC
Dana-Faber Cancer Institute - Boston MA
Brigham and Women's Hospital - Boston MA
The United States of America as represented by the Department of Veterans Affairs - Washington DC
Dana-Faber Cancer Institute - Boston MA
Brigham and Women's Hospital - Boston MA
International Classification:
C07H 21/04, C12N 15/12, C12N 15/63, C12N 5/07, C12N 15/09
US Classification:
536 235, 435 691, 4353201, 435325
Abstract:
This disclosure provides tyrosine kinase protein and nucleic acid variants, particularly PDGFRA variants, which are activating forms of these molecules and are linked to neoplasms and/or the development or progression of cancer. The disclosure further provides methods of diagnosis and prognosis, and development of new therapeutic agents using these molecules and fragments thereof, and kits for employing these methods and compositions.
Monoclonal Antibodies Specific For Pancreatic Neoplasia Cells
US Patent:
2011017, Jul 14, 2011
Filed:
Sep 9, 2009
Appl. No.:
13/062942
Inventors:
Phillip R. Streeter - Portland OR, US
Markus Grompe - Portland OR, US
Karin M. Hardiman - Portland OR, US
Brett C. Sheppard - Portland OR, US
Christopher L. Corless - Portland OR, US
Terry K. Morgan - Portland OR, US
Markus Grompe - Portland OR, US
Karin M. Hardiman - Portland OR, US
Brett C. Sheppard - Portland OR, US
Christopher L. Corless - Portland OR, US
Terry K. Morgan - Portland OR, US
International Classification:
A61K 39/395, G01N 33/53, C12N 9/96, C12N 5/10, C12N 5/16, C12N 5/02, C12N 15/63, C07K 16/18, C07H 21/04
US Classification:
4241331, 4241411, 435 71, 435188, 435325, 435326, 435375, 435378, 4353201, 5303873, 5303881, 5303913, 5303917, 536 2353
Abstract:
Isolated monoclonal antibodies are disclosed herein that specifically bind a cell surface antigen expressed on the human pancreatic cancer cells or precancerous pancreatic cancer cells. Humanized forms of these antibodies, functional fragments of these antibodies, and hybridomas producing these antibodies are also disclosed. The antibodies can be conjugated to an effector molecule, such as a detectable marker, a therapeutic agent, or a toxin. The antibodies can be used for in vitro or in vivo pancreatic cancer diagnosis or disease monitoring via detection of pancreatic cancer cells or the pancreatic cancer cell surface antigen. Methods of treating a pancreatic cancer by administration of the antibodies are also disclosed.
Methods Of Identifying And Treating Individuals Exhibiting Mutant Kit Protein
US Patent:
2009022, Sep 3, 2009
Filed:
Jun 9, 2006
Appl. No.:
11/921781
Inventors:
Francis Y. Lee - Yardley PA, US
Michael C. Heinrich - Lake Oswego OR, US
Christopher L. Corless - Portland OR, US
Michael C. Heinrich - Lake Oswego OR, US
Christopher L. Corless - Portland OR, US
International Classification:
A61K 31/496, C12Q 1/48, C12Q 1/68, A61P 43/00
US Classification:
51425219, 435 15, 435 6
Abstract:
The invention described herein relates to methods of identifying and treating individuals with protein tyrosine kinase associated disorders that have, or may, become resistant to treatment with a kinase inhibitor such as imatinib due to a gain-of-function mutation in KIT tyrosine kinase.